Suppression of adiponectin gene expression by histone deacetylase inhibitor valproic acid

Endocrinology

Volumn 147, Issue 2, 2006, Pages 865-874

  Qiao, Liping ^a   Schaack, Jerome ^b   Shao, Jianhua ^a  

^a UNIVERSITY OF KENTUCKY   (United States)

^b UNIVERSITY OF COLORADO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADIPONECTIN; CCAAT ENHANCER BINDING PROTEIN ALPHA; HISTONE DEACETYLASE INHIBITOR; LUCIFERASE; MESSENGER RNA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA 2; STEROID REGULATORY ELEMENT BINDING PROTEIN 1; UNCLASSIFIED DRUG; VALPROIC ACID;

ACETYLATION; ADIPOCYTE; ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; BINDING AFFINITY; CELL DIFFERENTIATION; CELL STRAIN 3T3; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; CORRELATION ANALYSIS; DOSE TIME EFFECT RELATION; DOWN REGULATION; EMBRYO; ENZYME ACTIVITY; ENZYME INHIBITION; FIBROBLAST; GENE EXPRESSION REGULATION; GENETIC TRANSCRIPTION; MALE; MOUSE; MOUSE STRAIN; NONHUMAN; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN EXPRESSION; STATISTICAL SIGNIFICANCE;

3T3-L1 CELLS; ADIPOCYTES; ADIPONECTIN; ANALYSIS OF VARIANCE; ANIMALS; ANTICONVULSANTS; CCAAT-ENHANCER-BINDING PROTEIN-ALPHA; DOSE-RESPONSE RELATIONSHIP, DRUG; ENZYME INHIBITORS; GENE EXPRESSION REGULATION; HISTONE DEACETYLASES; MALE; MICE; MICE, INBRED C57BL; PPAR GAMMA; PROMOTER REGIONS (GENETICS); RNA, MESSENGER; STATISTICS, NONPARAMETRIC; TIME FACTORS; TRANS-ACTIVATION (GENETICS); VALPROIC ACID;

EID: 30944450833     PISSN: 00137227     EISSN: 00137227     Source Type: Journal    
DOI: 10.1210/en.2005-1030     Document Type: Article

References (51)

1. Gurvich N, Klein PS 2002 Lithium and valproic acid: parallels and contrasts in diverse signaling contexts. Pharmacol Ther 96:45-66
2. Genton P, Bauer J, Duncan S, Taylor AE, Balen AH, Eberle A, Pedersen B, Salas-Puig X, Sauer MV 2001 On the association between Valproate and polycystic ovary syndrome. Epilepsia 42:295-304
3. Devlin MJ, Yanovski SZ, Wilson GT 2000 Obesity: what mental health professionals need to know. Am J Psychiatry 157:854-866
4. Corman C, Leung N, Guberman A 1997 Weight gain in epileptic patients during treatment with valproic acid: a retrospective study. Can J Neurol Sci 24:240-244
5. Verrotti A, Basciani F, De Simone M, Trotta D, Morgese G, Chiarelli F 2002 Insulin resistance in epileptic girls who gain weight after therapy with valproic acid. J Child Neurol 17:265-268
6. Scherer PE, Williams S, Fogliano M, Baldini G, Lodish HF 1995 A novel serum protein similar to C1q, produced exclusively in adipocytes. J Biol Chem 270:26746-26749
7. Hu E, Liang P, Spiegelman BM 1996 AdipoQ is a novel adipose-specific gene dysregulated in obesity. J Biol Chem 271:10697-10703
8. Maeda K, Okubo K, Shimomura I, Funahashi T, Matsuzawa Y, Matsubara K 1996 cDNA cloning and expression of a novel adipose specific collagen-like factor, apM1 (AdiPose most abundant gene transcript 1). Biochem Biophys Res Commun 221:286-289
9. Nakano Y, Tobe T, Choi-Miura NH, Mazda T, Tomita M 1996 Isolation and characterization of GBP28, a novel gelatin-binding protein purified from human plasma. J Biochem (Tokyo) 120:803-812
10. Kim S, Moustaid-Moussa N 2000 Secretory, endocrine and autocrine/paracrine function of the adipocyte. J Nutr 130:3110S-3115S
11. Kahn BB, Flier JS 2000 Obesity and insulin resistance. J Clin Invest 106:473-481
12. Diez JJ, Iglesias P 2003 The role of the novel adipocyte-derived hormone adiponectin in human disease. Eur J Endocrinol 148:293-300
13. Stefan N, Stumvoll M 2002 Adiponectin - its role in metabolism and beyond. Horm Metab Res 34:469-474
14. Berg AH, Combs TP, Du X, Brownlee M, Scherer PE 2001 The adipocyte-secreted protein Acrp30 enhances hepatic insulin action. Nat Med 7:947-953
15. Fruebis J, Tsao TS, Javorschi S, Ebbets-Reed D, Erickson MR, Yen FT, Bihain BE, Lodish HF 2001 Proteolytic cleavage product of 30-kDa adipocyte complement-related protein increases fatty acid oxidation in muscle and causes weight loss in mice. Proc Natl Acad Sci USA 98:2005-2010
16. Yamauchi T, Kamon J, Minokoshi Y, Ito Y, Waki H, Uchida S, Yamashita S, Noda M, Kita S, Ueki K, Eto K, Akanuma Y, Froguel P, Foufelle F, Ferre P, Carling D, Kimura S, Nagai R, Kahn BB, Kadowaki T 2002 Adiponectin stimulates glucose utilization and fatty-acid oxidation by activating AMP-activated protein kinase. Nat Med 8:1288-1295
17. Yamauchi T, Kamon J, Ito Y, Tsuchida A, Yokomizo T, Kita S, Sugiyama T, Miyagishi M, Hara K, Tsunoda M, Murakami K, Ohteki T, Uchida S, Takekawa S, Waki H, Tsuno NH, Shibata Y, Terauchi Y, Froguel P, Tobe K, Koyasu S, Taira K, Kitamura T, Shimizu T, Nagai R, Kadowaki T 2003 Cloning of adiponectin receptors that mediate antidiabetic metabolic effects. Nature 423:762-769
18. Tomas E, Tsao TS, Saha AK, Murrey HE, Zhang Cc C, Itani SI, Lodish HF, Ruderman NB 2002 Enhanced muscle fat oxidation and glucose transport by ACRP30 globular domain: acetyl-CoA carboxylase inhibition and AMP-activated protein kinase activation. Proc Natl Acad Sci USA 99:16309-16313
19. Arita Y, Kihara S, Ouchi N, Takahashi M, Maeda K, Miyagawa J, Hotta K, Shimomura I, Nakamura T, Miyaoka K, Kuriyama H, Nishida M, Yamashita S, Okubo K, Matsubara K, Muraguchi M, Ohmoto Y, Funahashi T, Matsuzawa Y 1999 Paradoxical decrease of an adipose-specific protein, adiponectin, in obesity. Biochem Biophys Res Commun 257:79-83
20. Hotta K, Funahashi T, Arita Y, Takahashi M, Matsuda M, Okamoto Y, Iwahashi H, Kuriyama H, Ouchi N, Maeda K, Nishida M, Kihara S, Sakai N, Nakajima T, Hasegawa K, Muraguchi M, Ohmoto Y, Nakamura T, Yamashita S, Hanafusa T, Matsuzawa Y 2000 Plasma concentrations of a novel, adipose-specific protein, adiponectin, in type 2 diabetic patients. Arterioscler Thromb Vasc Biol 20:1595-1599
21. Statnick MA, Beavers LS, Conner LJ, Corominola H, Johnson D, Hammond CD, Rafaeloff-Phail R, Seng T, Suter TM, Sluka JP, Ravussin E, Gadski RA, Caro JF 2000 Decreased expression of apM1 in omental and subcutaneous adipose tissue of humans with type 2 diabetes. Int J Exp Diabetes Res 1:81-88
22. Tsao TS, Lodish HF, Fruebis J 2002 ACRP30, a new hormone controlling fat and glucose metabolism. Eur J Pharmacol 440:213-221
23. Verrotti A, Basciani F, Morresi S, de Martino M, Morgese G, Chiarelli F 1999 Serum leptin changes in epileptic patients who gain weight after therapy with valproic acid. Neurology 53:230-232
24. Lagace DC, McLeod RS, Nachtigal MW 2004 Valproic acid inhibits leptin secretion and reduces leptin messenger ribonucleic acid levels in adipocytes. Endocrinology 145:5493-5503
25. Struhl K 1998 Histone acetylation and transcriptional regulatory mechanisms. Genes Dev 12:599-606
26. Gottlicher M, Minucci S, Zhu P, Kramer OH, Schimpf A, Giavara S, Sleeman JP, Lo Coco F, Nervi C, Pelicci PG, Heinzel T 2001 Valproic acid defines a novel class of HDAC inhibitors inducing differentiation of transformed cells. EMBO J 20:6969-6978
27. Phiel CJ, Zhang F, Huang EY, Guenther MG, Lazar MA, Klein PS 2001 Histone deacetylase is a direct target of valproic acid, a potent anticonvulsant, mood stabilizer, and teratogen. J Biol Chem 276:36734-36741
28. Nau H 1985 Teratogenic valproic acid concentrations: infusion by implanted minipumps vs conventional injection regimen in the mouse. Toxicol Appl Pharmacol 80:243-250
29. Schank JR, Liles LC, Weinshenker D 2005 Reduced anticonvulsant efficacy of valproic acid in dopamine β-hydroxylase knockout mice. Epilepsy Res 65:23-31
30. Orlicky DJ, DeGregori J, Schaack J 2001 Construction of stable coxsackievirus and adenovirus receptor-expressing 3T3-L1 cells. J Lipid Res 42:910-915
31. Ross SA, Song X, Burney MW, Kasai Y, Orlicky DJ 2003 Efficient adenovirus transduction of 3T3-L1 adipocytes stably expressing coxsackie-adenovirus receptor. Biochem Biophys Res Commun 302:354-358
32. Qiao L, MacLean PS, Schaack J, Orlicky DJ, Darimont C, Pagliassotti M, Friedman JE, Shao J 2005 C/EBPα regulates human adiponectin gene transcription through an intronic enhancer. Diabetes 54:1744-1754
33. Shao J, Qiao L, Janssen RC, Pagliassotti M, Friedman JE 2005 Chronic hyperglycemia enhances PEPCK gene expression and hepatocellular glucose production via elevated liver activating protein/liver inhibitory protein ratio. Diabetes 54:976-984
34. Chakrabarti SK, James JC, Mirmira RG 2002 Quantitative assessment of gene targeting in vitro and in vivo by the pancreatic transcription factor, Pdx1. Importance of chromatin structure in directing promoter binding. J Biol Chem 277:13286-13293
35. Hazel M, Cooksey RC, Jones D, Parker G, Neidigh JL, Witherbee B, Gulve EA, McClain DA 2004 Activation of the hexosamine signaling pathway in adipose tissue results in decreased serum adiponectin and skeletal muscle insulin resistance. Endocrinology 145:2118-2128
36. Lagace DC, Nachtigal MW 2004 Inhibition of histone deacetylase activity by valproic acid blocks adipogenesis. J Biol Chem 279:18851-18860
37. Duan H, Heckman CA, Boxer LM 2005 Histone deacetylase inhibitors down-regulate bcl-2 expression and induce apoptosis in t(14;18) lymphomas. Mol Cell Biol 25:1608-1619
38. Sanjo Y, Yokoyama T, Sato S, Ikeda K, Nakajima R 1999 Ergonomic automated anesthesia recordkeeper using a mobile touch screen with voice navigtion. J Clin Monit Comput 15:347-356
39. Gurvich N, Tsygankova OM, Meinkoth JL, Klein PS 2004 Histone deacetylase is a target of valproic acid-mediated cellular differentiation. Cancer Res 64:1079-1086
40. Das K, Lin Y, Widen E, Zhang Y, Scherer PE 2001 Chromosomal localization, expression pattern, and promoter analysis of the mouse gene encoding adipocyte-specific secretory protein Acrp30. Biochem Biophys Res Commun 280:1120-1129
41. Gustafson B, Jack MM, Cushman SW, Smith U 2003 Adiponectin gene activation by thiazolidinediones requires PPARγ2, but not C/EBPα-evidence for differential regulation of the aP2 and adiponectin genes. Biochem Biophys Res Commun 308:933-939
42. Park S-k, Oh S-Y, Lee M-Y, Yoon S, Kim K-S, Kim J-w 2004 CCAAT/enhancer binding protein and nuclear factor-Y regulate adiponectin gene expression in adipose tissue. Diabetes 53:2757-2766
43. Ferin M, Morrell M, Xiao E, Kochan L, Qian F, Wright T, Sauer M 2003 Endocrine and metabolic responses to long-term monotherapy with the antiepileptic drug valproate in the normally cycling rhesus monkey. J Clin Endocrinol Metab 88:2908-2915
44. Lagace DC, Nachtigal MW 2003 Valproic acid fails to induce polycystic ovary syndrome in female rats. Prog Neuropsychopharmacol Biol Psychiatry 27:587-594
45. Wolden-Hanson T, Gidal BE, Atkinson RL 1998 Evaluation of a rat model of valproate-induced obesity. Pharmacotherapy 18:1075-1081
46. Chapman JB, Cutler MG 1984 Sodium valproate: effects on social behaviour and physical development in the mouse. Psychopharmacology (Berl) 83:390-396
47. Nusinzon I, Horvath CM 2005 Histone deacetylases as transcriptional activators? Role reversal in inducible gene regulation. Sci STKE 2005:re11
48. Van Lint C, Emiliani S, Verdin E 1996 The expression of a small fraction of cellular genes is changed in response to histone hyperacetylation. Gene Expr 5:245-253
49. Takahashi I, Miyaji H, Yoshida T, Sato S, Mizukami T 1996 Selective inhibition of IL-2 gene expression by trichostatin A, a potent inhibitor of mammalian histone deacetylase. J Antibiot (Tokyo) 49:453-457
50. Huang N, Katz JP, Martin DR, Wu GD 1997 Inhibition of IL-8 gene expression in Caco-2 cells by compounds which induce histone hyperacetylation. Cytokine 9:27-36
51. Park B-H, Qiang L, Farmer SR 2004 Phosphorylation of C/EBPβ at a consensus extracellular signal-regulated kinase/glycogen synthase kinase 3 site is required for the induction of adiponectin gene expression during the differentiation of mouse fibroblasts into adipocytes. Mol Cell Biol 24:8671-8680